Research Article

Effects of Selenium-Enriched Protein from *Ganoderma lucidum* on the Levels of IL-1\(\beta\) and TNF-\(\alpha\), Oxidative Stress, and NF-\(\kappa B\) Activation in Ovalbumin-Induced Asthmatic Mice

Guan Min-chang, 1 Tang Wei-hong, 1 Xu Zhen, 2 and Sun Jie 2

1 Taizhou Enze Medical Center Luqiao Hospital, Zhejiang 318050, China
2 Huzhou Central Hospital, Zhejiang 313000, China

Correspondence should be addressed to Sun Jie; sunjiehuzhou@qq.com

Received 31 October 2013; Accepted 23 December 2013; Published 10 February 2014

Academic Editor: Chunchao Han

Copyright © 2014 Guan Min-chang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The purpose of this study was to compare the effect and toxicity of organic selenium (Pro-Se) with inorganic selenium (IOSe) in preventing asthma in ovalbumin-induced asthmatic mice. After the mice were treated orally with Pro-Se and IOSe, respectively, the plasma Se levels, Se accumulation in liver and kidney, tumor necrosis factor alpha (TNF-\(\alpha\)), interleukin 1 beta (IL-1\(\beta\)), oxidative stress, and NF-\(\kappa B\) activation in lung were examined. The results showed that the serumal Se levels in the mice fed the Pro-Se were significant (\(P<0.01\)) elevations. It results in restoration of the level of endogenous antioxidant enzyme, lower levels of TNF-\(\alpha\) and IL-1\(\beta\), and activated NF-\(\kappa B\) in asthmatic mice. Our experiments have demonstrated profound differences between the activities of organic selenium and inorganic selenium in experimental conditions. These data provide an important proof of the concept that organic selenium might be a new potential therapy for the management of childhood asthma in humans.

1. Introduction

Asthma is a chronic disease associated with airway hyper-responsiveness, airway obstruction, and airway remodelling [1, 2]. The principal pathophysiology of asthma is chronic inflammation of the lower respiratory tract [3]. Anti-inflammatory agents such as inhaled steroids and leukotriene receptor antagonists along with long acting bronchodilators are the mainstay of asthma pharmacotherapy. However, potential long term side effects, prohibitive costs, and suboptimal adherence to asthma medications are ongoing challenges to optimal asthma control. Treatment options are, therefore, quite limited for asthma and the need to search for other therapies has been recognized by many experts in the field [4, 5].

The trace element selenium (Se) is an essential nutrient for all mammalian species and is of fundamental importance for human biology. Deficient Se intake may dramatically affect inflammation and immune responses. Also, the use of Se supplementation to increase Se status to supraphysiological levels may be exploited to modulate immune processes that drive certain health disorders, such as the T helper 2 (Th2) responses that drive allergic asthma [6, 7]. Therefore, Se intake has been hypothesized to play a role in the development and/or severity of this complex disease, asthma.

However, Mahan and Kim [8] suggested that Se may not be as biologically effective as the Se indigenous in grains, which is primarily in the organic form of selenomethionine. Mahan and Parrett [9] found that total Se excretion decreased and tissue retention increased when an organic, rather than an inorganic, source of Se was fed. Further, organic selenium is reported to be better absorbed, has higher bioavailability, and is less toxic than inorganic selenium [10–12]. In the present study, we isolated selenium-contained protein (Pro-Se) with different selenium content, indicated the organic selenium, from the *Ganoderma lucidum*, and compared the effect and toxicity of organic selenium in preventing asthma with those of inorganic selenium (IOSe).
2. Materials and Methods

2.1. Chemicals. Sodium selenite was purchased from Anhui Star New Material Technology Co., Ltd., China.

2.2. Sodium Selenite Solution (IOSe). Sodium selenite was dissolved in normal saline. An ampule was filled with 0.4 mL of IOSe with 0.104 µg sodium selenite.

2.3. Selenium-Contained Protein (Pro-Se). *Ganoderma lucidum* was cultured on the medium which was composed of peptone (10.0 g/L), beef extract (10.0 g/L), yeast extract (5.0 g/L), K₂HPO₄ (2.0 g/L), triammonium citrate (2.0 g/L), sodium acetate (5.0 g/L), glucose, tween 80 (1.0 mL/L), MgSO₄·H₂O (0.58 g/L), MnSO₄·H₂O (0.25 g/L), corn steep liquor (3.0 g/L), and cysteine hydrochloride (0.3 g/L). After 6 h, sodium selenite of different concentrations (0, 2.5, 5.0 mg/mL) was added to the medium. The Se-enriched *Ganoderma lucidum* were marked with Se0, Se2.5, and Se5.0, respectively, according to the sodium selenite concentration. The Se-enriched *Ganoderma lucidum* was removed by centrifugation after cultured with sodium selenite for another 12 h, and then it was preserved in the dark at room temperature after freeze drying (~50°C, under vacuum).

The protein was isolated according to the method of Kadrabova et al. [13]. 3.0 g of each kind of dry bacteria samples (Se0, Se2.5, and Se5.0) was dissolved in cold sodium hydroxide solution (0.25 M); the bacteria samples were bro- samplers (Se0, Se2.5, and Se5.0) was dissolved in cold sodium hydroxide solution (0.25 M); the bacteria samples were bro- samples (Se0, Se2.5, and Se5.0) was dissolved in cold sodium hydroxide solution (0.25 M); the bacteria samples were bro- samples (Se0, Se2.5, and Se5.0) was dissolved in cold sodium hydroxide solution (0.25 M); the bacteria samples were bro-

2.4. Animals. Twenty-to-22-day-old female BALB/c mice, weighing from 12 g to 15 g, were obtained from the Experimental Animal Center of Zhejiang. Mice were housed with free access to food and water in a room with an ambient temperature of 22 ± 2°C and a 12:12 h light/dark cycle. All experiments were carried out in strict accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. The normal basal diet (NBD) for the mice was also purchased from the Center of Laboratory Animals, Zhejiang University. The NBD containing 0.05 µg/g of Se in a pellet form was formulated to meet the nutrient requirements for normal laboratory mice.

2.5. Induction of Model of Asthma. Mice were sensitized via 2 intraperitoneal injections of 10 µg of ovalbumin (grade V, ≥98% pure, Sigma, St. Louis, MO, USA) with alum adjuvant on days 0 and 14 of the experiment. Starting on day 21, the mice, housed in whole-body exposure chambers, were exposed to 1% aerosolized ovalbumin for 30 min a day, 3 days a week, for 9 weeks. The temperature was kept at 20°C to 25°C and the relative humidity at 40% to 60%.

2.6. Experimental Design. Mice were randomly assigned to six groups: control group with saline treatment, asthmatic group with saline treatment, and asthmatic group treated with 0.4 mL Pro-Se0 (0 µg selenium), 0.4 mL Pro-Se2.5 (0.104 µg selenium), 0.4 mL Pro-Se5.0 (0.1332 µg selenium), and 0.4 mL of IOSe (0.104 µg selenium). All animals surviving after 30 days were killed. The blood samples were drawn from orbital vein from all the groups and serum was separated for biochemical estimations. Tissue samples of lung, liver, and kidney were dissected from the visceral tissues. After washing with saline, the tissue samples were blotted dry and weighed. All samples were stored at −80°C for future analysis.

2.7. Serum Selenium Measurement. Plasma Se levels were determined by means of an atomic absorption spectrometer (AAS-3200, Shanghai, China). Plasma was diluted (1:3) with 0.05% Triton-X 100 and 0.05% antifoam B solution. NiNO (0.2% w/w) was used as a modifier for Se measurement. All determinations were run in duplicate, and individual values were averaged. The highest standard addition concentration was 100 µg/L for Se determination. The autosampler system was used in the automix mode and with sample intake of the graphite tube of 1 µL/s. The total volume inserted in the tube was 20 µL (5 µL of matrix modifier, 10 µL of sample, and 5 µL of standard solution). Absorption readings were measured as peak height. The variation coefficient for replicate measurement was <3%. The lowest threshold was 10 µg/L for Se detection.

2.8. Determination of Se Accumulation in Liver and Kidney. Selenium concentrations were determined using atomic absorption (AA). Weighed aliquots of frozen tissues were digested in 3 stages: the first using 5 mL mixed acids (4:1 of nitric acid : perchloric acid), the second using a combination of 2 mL HNO₃ and 30% H₂O₂, and finally using 2 mL HNO₃. All digestions were performed at 130°C until the acid was completely evaporated and the residue dried before the next acid stage was started. After the third acid treatment, 1% HNO₃ was added to the digests and heated at 80°C for 1 h. After cooling, the sample volume was measured and analyzed.

2.9. Estimation of Pro-Se on Oxidative Stress. Serum was used for the assay of glutathione (GSH) content, Lipid peroxidation (LPO), glutathione peroxidase (GPx) activity, glutathione reductase (GR) activity, catalase (CAT) activity, Na⁺K⁺ ATPase activity, and glutathione S transferase (GST) activity.
2.10. Measurement of Pro-Se on IL-1β and TNF-α. The concentration of interleukin-1β (IL-1β) and TNF-α in the plasma was determined using a commercial ELISA kit (Shanghai Jinma Biological Technology Inc., China) according to the manufacturer’s instructions.

2.11. Measurement of Pro-Se on NF-κB Activation in Lung. For measurement of NF-κB activation in the lung, nuclear protein from lung samples was extracted using a commercial kit (Shanghai Jinma Biological Technology, Inc., China). Activation of NF-κB in the lung was determined using an ELISA kit (Shanghai Jinma Biological Technology, Inc., China), following the manufacturer’s instruction. This kit specifically detects the p50 member of NF-κB.

2.12. Data Analysis. Group means were compared by ANOVA with GraphPad Prism (GraphPad Software, Inc.). Multiple comparison tests were performed with Tukey for significant differences at $P < 0.05$.

3. Results

3.1. The Effect of Pro-Se on Selenium Levels in Serum. As shown in Table 1, Pro-Se significantly increased Se content in mice serum. Compared to the control without diet supplementation, serum Se levels were improved by 10.4% ($P > 0.05$), 27.1% ($P < 0.05$), and 64.6% ($P < 0.01$) with IOSe, Pro-Se2.5, and Pro-Se5.0, respectively. Pro-Se was more favorable to Se absorption and deposition in rats than IOSe, which indicated that the Pro-Se in this study showed a higher bioavailability in mice.

3.2. Se Accumulation in Liver and Kidney. The organ masses of liver and kidney were significantly different between Pro-Se and IOSe groups ($P < 0.05$). However, there was no significant difference in organ masses of liver and kidney between the Pro-Se groups ($P > 0.05$). It is implied that IOSe is toxic to animals, while Pro-Se is essentially nontoxic (Table 2). The Se contents in animal tissues were measured following the studies and the results are shown in Figure 1. The Se content in tissues of Pro-Se2.5 group was 4.21 ppm and 5.56 ppm (liver and kidney) while IOSe groups exhibited elevated levels of Se content, but not to a statistically significant degree. It is implied that Pro-Se could reduce Se accumulation in animal tissues to a certain extent.

3.3. The Effect of Pro-Se on Oxidative Stress. In this study, a significant increase in the activity of LPO was observed in asthmatic group, as compared to the control group ($P < 0.001$), whereas Pro-Se2.5 and Pro-Se5.0 treatment significantly ($P < 0.05$, $P < 0.01$, resp.) resulted in decreased LPO levels when compared with asthmatic group (Table 3). Concentrations of GSH were lower in asthmatic group than those in control group (Table 3). Pro-Se produced the increase in the level of GSH. The activity of endogenous antioxidant enzymes was decreased significantly ($P < 0.01$) in the asthmatic group, as compared to the control group, whereas in the Pro-Se2.5 and Pro-Se5.0 groups, Pro-Se treatment showed a significant ($P < 0.05–0.01$) restoration in the level of various enzymes as compared with asthmatic group (Table 3). However, there was no significant difference between the asthmatic group and the IOSe treated group (Table 3).

3.4. The Effect of Pro-Se on Inflammatory Mediators. Figure 2 shows that ovalbumin-induced asthma significantly

---

**Table 1:** The effect of Pro-Se and IOSe on selenium levels in serum ($n = 10$).

| Different groups | Selenium level ($\mu$g/mL) |
|------------------|---------------------------|
| Asthmatic group with saline | 0.48 ± 0.03 |
| Asthmatic group with Pro-Se5.0 | 0.79 ± 0.09** |
| Asthmatic group with Pro-Se2.5 | 0.61 ± 0.01* |
| Asthmatic group with Pro-Se0 | 0.34 ± 0.06 |
| Asthmatic group with IOSe | 0.53 ± 0.06 |
| Control group | 0.72 ± 0.03 |

*$P < 0.05$*, **$P < 0.01$** versus saline-treated.

**Table 2:** Effects of Pro-Se and IOSe on organ masses of mice ($n = 10$).

| Mouse group | Liver weights (g) | Kidney weights (g) |
|-------------|------------------|------------------|
| Control group | 1.47 ± 0.05$a$ | 0.49 ± 0.04$a$ |
| Asthmatic group with saline | 1.30 ± 0.07$b$ | 0.37 ± 0.03$b$ |
| Asthmatic group with IOSe | 1.31 ± 0.06$b$ | 0.34 ± 0.03$b$ |
| Asthmatic group with Pro-Se0 | 1.48 ± 0.07$a$ | 0.48 ± 0.04$a$ |
| Asthmatic group with Pro-Se2.5 | 1.47 ± 0.03$a$ | 0.47 ± 0.02$a$ |
| Asthmatic group with Pro-Se5.0 | 1.45 ± 0.06$a$ | 0.49 ± 0.02$a$ |

The different letters in the same column indicate a statistical difference ($P < 0.05$).
Table 3: Effect of Pro-Se and IOSe on GSH and LPO levels and the activity of various enzymes.

| Different groups                | GSH (nmol/mL) | LPO (nmol/mL) | GPx           | GR            | GST           | CAT           | Na⁺K⁺ATPase   |
|--------------------------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|
| Control group                  | 1.830 ± 0.011∗| 14.33 ± 0.56***| 16.00 ± 2.23**| 36.56 ± 2.56**| 17.44 ± 1.23**| 7.22 ± 0.32**| 4.56 ± 0.60∗  |
| Asthmatic group with saline    | 1.112 ± 0.011  | 20.01 ± 1.41  | 7.89 ± 0.33   | 21.11 ± 2.23  | 9.07 ± 1.11   | 4.66 ± 0.10   | 2.22 ± 0.20   |
| Asthmatic group with IOSe      | 1.401 ± 0.022∗| 19.82 ± 1.22  | 8.10 ± 0.32   | 24.31 ± 2.02  | 10.60 ± 0.66  | 4.88 ± 0.32   | 3.00 ± 0.31   |
| Asthmatic group with Pro-Se0   | 1.300 ± 0.011∗| 17.80 ± 1.11  | 6.12 ± 0.30   | 20.31 ± 2.00  | 9.60 ± 0.33   | 3.80 ± 0.25   | 2.00 ± 0.30   |
| Asthmatic group with Pro-Se2.5 | 1.500 ± 0.021∗| 17.23 ± 2.00∗ | 13.23 ± 1.30∗ | 27.50 ± 2.11**| 15.50 ± 1.15* | 5.45 ± 0.55*  | 4.32 ± 0.30*  |
| Asthmatic group with Pro-Se5.0 | 1.500 ± 0.033∗| 14.33 ± 3.21* | 14.11 ± 1.12* | 30.21 ± 6.03**| 17.66 ± 2.33**| 6.66 ± 0.44*  | 4.11 ± 0.21*  |

Values are shown as means ± SEM. ∗P < 0.05 versus asthmatic group, **P < 0.01 versus asthmatic group, and ***P < 0.001 versus asthmatic group.

3.5. The Effect of Pro-Se on Activation of NF-κB. As shown in Figure 4, asthma significantly induced activated NF-κB above control levels, and as hypothesized, Pro-Se2.5 and Pro-Se5.0 significantly suppressed this response. However, the same results did not occur in the Pro-Se0 treated group and IOSe treated group.

4. Discussion

It has been reported that selenium supplementation might be beneficial to patients with intrinsic asthma [13]. However, the less absorbed and bioavailability limits its role as a therapeutic agent for asthma [10–12]. In the present study, we isolated Pro-Se from *Ganoderma lucidum* and compared the difference of the antioxidant and anti-inflammatory activities between organic selenium (Pro-Se) and inorganic selenium (IOSe) in the model of asthma.

In this study, we have demonstrated a correlation between Se and asthma. Asthma led to a decrease in serum Se level. In our *in vivo* study, we have presented evidence for a significant increase in serum Se level in Pro-Se treated asthmatic mice while IOSe did not exhibit any such effects. It indicates Pro-Se may improve the bioavailability of Se in mice. At the same time, the Se content in tissues of Pro-Se2.5 group was lower than those of IOSe groups. It is implied that Pro-Se could reduce Se accumulation in animal tissues to a certain extent.

The lungs of asthmatic patients are exposed to oxidative stress due to the generation of reactive oxygen as a consequence of chronic airway inflammation. The available evidence tends to support the concept that the oxidant/antioxidant equilibrium is disturbed in asthma [14,
selenium in experimental conditions. These data provide an important proof of the concept that organic selenium might be a new potential therapy for the management of asthma in humans. The potential application of organic selenium needs to be further studied.

**Conflict of Interests**

The authors declare that there is no conflict of interests regarding the publication of this paper.

**References**

[1] D. K. Agrawal and Z. Shao, "Pathogenesis of allergic airway inflammation," *Current Allergy and Asthma Reports*, vol. 10, no. 1, pp. 39–48, 2010.

[2] H. S. McGee, A. L. Stallworth, T. Agrawal, Z. Shao, L. Lorence, and D. K. Agrawal, "Fms-like tyrosine kinase 3 ligand decreases T helper type 17 cells and suppressors of cytokine signaling proteins in the lung of house dust mite-sensitized and -challenged mice," *American Journal of Respiratory Cell and Molecular Biology*, vol. 43, no. 5, pp. 520–529, 2010.

[3] F. E. Hargreave and P. Nair, "The definition and diagnosis of Asthma," *Clinical and Experimental Allergy*, vol. 39, no. 11, pp. 1652–1658, 2009.

[4] J. Chakir, Q. Hamid, M. Bossé, L.-P. Boulet, and M. Laviolette, "Bronchial inflammation in corticosteroid-sensitive and corticosteroid-resistant asthma at baseline and on oral corticosteroid treatment," *Clinical and Experimental Allergy*, vol. 32, no. 4, pp. 578–582, 2002.

[5] Y. Sumi and Q. Hamid, "Airway remodeling in asthma," *Allergy International*, vol. 56, no. 4, pp. 341–348, 2007.

[6] J. Stone, L. J. Hinks, R. Beasley, S. T. Holgate, and B. A. Clayton, "Reduced selenium status of patients with asthma," *Clinical Science*, vol. 77, no. 5, pp. 495–500, 1989.

[7] A. Flatt, N. Pearce, C. D. Thomson, M. R. Sears, M. F. Robinson, and R. Beasley, "Reduced selenium in asthmatic subjects in New Zealand," *Thorax*, vol. 45, no. 2, pp. 95–99, 1990.

[8] D. C. Mahan and Y. Y. Kim, "Effect of inorganic or organic selenium at two dietary levels on reproductive performance and tissue selenium concentrations in first-parity gilts and their progeny," *Journal of Animal Science*, vol. 74, no. 11, pp. 2711–2718, 1996.

[9] D. C. Mahan and N. A. Parrett, "Evaluating the efficacy of selenium-enriched yeast and sodium selenite on tissue selenium retention and serum glutathione peroxidase activity in grower and finisher swine," *Journal of Animal Science*, vol. 74, no. 12, pp. 2967–2974, 1996.

[10] Z. Gačević, G. Kralik, E. Has-Schön, and V. Pavić, "Effects of organic selenium supplemented to layer diet on table egg freshness and selenium content," *Italian Journal of Animal Science*, vol. 9, no. 2, pp. 189–199, 2009.

[11] F. Z. Küükbay, H. Yazlak, I. Karaca et al., "The effects of dietary organic or inorganic selenium in rainbow trout (*Oncorhynchus mykiss*) under crowding conditions," *Aquaculture Nutrition*, vol. 15, no. 6, pp. 569–576, 2009.

[12] J. B. Taylor, J. W. Finley, and J. S. Caton, "Effect of the chemical form of supranutritional selenium on selenium load and selenoprotein activities in virgin, pregnant, and lactating rats," *Journal of Animal Science*, vol. 83, no. 2, pp. 422–429, 2005.
[13] J. Kadrabova, A. Maďaric, Z. Kovacikova, F. Podivinsky, E. Ginter, and F. Gazdik, “Selenium status is decreased in patients with intrinsic asthma,” *Biological Trace Element Research*, vol. 52, no. 3, pp. 241–248, 1996.

[14] A. A. Andreadis, S. L. Hazen, S. A. A. Comhair, and S. C. Erzurum, “Oxidative and nitrosative events in asthma,” *Free Radical Biology and Medicine*, vol. 35, no. 3, pp. 213–225, 2003.

[15] P. A. J. Henricks and F. P. Nijkamp, “Reactive oxygen species as mediators in asthma,” *Pulmonary Pharmacology and Therapeutics*, vol. 14, no. 6, pp. 409–421, 2001.

[16] L. Hasselmark, R. Malmgren, O. Zetterstrom, and G. Unge, “Selenium supplementation in intrinsic asthma,” *Allergy*, vol. 48, no. 1, pp. 30–36, 1993.

[17] F. Gazdik, J. Kadrabova, and K. Gazdikova, “Decreased consumption of corticosteroids after selenium supplementation in corticoid-dependent asthmatics,” *Bratislavské Lekárské Listy*, vol. 103, no. 1, pp. 22–25, 2002.

[18] J. L. Stow, P. Ching Low, C. Offenhäuser, and D. Sangermani, “Cytokine secretion in macrophages and other cells: pathways and mediators,” *Immunobiology*, vol. 214, no. 7, pp. 601–612, 2009.

[19] A. Ugusman, Z. Zakaria, C. Kien Hui, and N. A. Megat Mohd Nordin, “*Piper sarmentosum* inhibits ICAM-1 and Nox4 gene expression in oxidative stress-induced human umbilical vein endothelial cells,” *BMC Complementary and Alternative Medicine*, vol. 11, article 31, 2011.